Oxford, UK 09 September 2011 – PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC (chemistry, manufacturing & controls) & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures’ asset divestment expertise in the life sciences sector.
Dr Fintan Walton, CEO, PharmaVentures commented, “We are delighted to have been chosen by Astex to assist in divesting this state-of-the-art facility, maximising return for the stakeholders. With 20 years’ experience of transactions, PharmaVentures can provide Astex with access to key decision makers in relevant companies with a view to safeguarding the future of the site.”
The facility is part of the recent integration of Astex Therapeutics Limited and SuperGen Inc. and provides an opportunity to build out a fully integrated CMC capability in a prime but low cost West Coast US location. The site’s team has significant experience in preclinical as well as Phase I, II and III drug product development as evidenced by over 30 patents and the successful oversight of a number of global regulatory filings.
PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals. The transactions team has an established track record in generating outstanding value for PharmaVentures’ clients and has assisted in over 100 transactions in the past 20 years.
For enquiries regarding this opportunity or how we can help your company to achieve its business goals, please contact:
Dr Jansen Jacob
Senior Advisor
PharmaVentures Ltd
jansen.jacob@pharmaventures.com
+44 7951 205420
– ends –